The successful data analysis for narsoplimab significantly reduces death risk in HSCT-TMA patients, which is a positive development for Omeros. The FDA's request for new statistical analysis was met, increasing the likelihood of approval by late 2025. This has led to a rebound in stock price. However, financial risks such as limited cash and potential market constraints due to generic competition and insurance issues could impact the company's financial health.